Back to today’s briefing

Story perspectives

July Spotlights Sarcoma Awareness, New Treatments Approved

6/29/2025

32 5

Summary

Story summary

July shines a spotlight on Sarcoma Awareness Month, drawing attention to the 15,000 annual diagnoses of this rare connective tissue cancer in the U.S. Exciting progress is underway as the FDA has approved Adaptimmune's Tecelra for synovial sarcoma. Meanwhile, critical decisions loom for Dizal's Sunvozertinib and Regeneron's therapies, fueling hope for those battling rare diseases.

1 of 1

Story summary

July shines a spotlight on Sarcoma Awareness Month, drawing attention to the 15,000 annual diagnoses of this rare connective tissue cancer in the U.S. Exciting progress is underway as the FDA has approved Adaptimmune's Tecelra for synovial sarcoma. Meanwhile, critical decisions loom for Dizal's Sunvozertinib and Regeneron's therapies, fueling hope for those battling rare diseases.